Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2012 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Return on Capital Employed of 9.85% for Q2 2026, down 1579.0% year-over-year from 0.67% in Q2 2025, and down 73.59% on a QoQ basis from 5.67% in Q4 2025.
Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2012 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Return on Capital Employed for 15 years, with the latest figure at 9.85% in Q2 2026.
- Return on Capital Employed for Q2 2026 came in at 9.85%, down 1579.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 9.85% (down 1579.0% YoY), and the FY2025 annual result was 5.81%, down 1373.0% from the prior year.
- Return on Capital Employed fell to 9.85% in Q2 2026, from 5.67% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 7.68% in Q4 2024 and troughed at 9.85% in Q2 2026.
- A 5-year average of 2.05% and a median of 3.0% in 2023 frame the typical range for Return on Capital Employed.
- The widest annual swing landed in 2025, when Return on Capital Employed soared 832 bps; it then plunged 1579 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 4.57% in 2022, then slumped by 112 bps to 0.53% in 2023, then jumped by 1545 bps to 7.68% in 2024, then slumped by 174 bps to 5.67% in 2025, then plunged by 74 bps to 9.85% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 9.85% in Q2 2026, 5.67% in Q4 2025, and 3.45% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | -9.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.85% |
| Dec 31, 2025 | -5.67% |
| Sep 30, 2025 | -3.45% |
| Jun 30, 2025 | 5.95% |
| Mar 31, 2025 | 6.93% |
| Dec 31, 2024 | 7.68% |
| Sep 30, 2024 | 5.71% |
| Jun 30, 2024 | 2.65% |
| Mar 31, 2024 | -1.39% |
| Dec 31, 2023 | -0.53% |
| Sep 30, 2023 | 3.00% |
| Jun 30, 2023 | 1.58% |
| Mar 31, 2023 | 4.86% |
| Dec 31, 2022 | 4.57% |
| Sep 30, 2022 | 1.85% |
| Jun 30, 2022 | 5.58% |
| Mar 31, 2022 | 5.42% |
| Dec 31, 2021 | 6.58% |
| Sep 30, 2021 | 9.25% |
| Jun 30, 2021 | 11.65% |